Alterity Therapeutics Files Application for Quotation of Securities

Alterity Therapeutics Limited, a development-stage biotechnology company, filed a Form 6-K on September 16, 2026, with the SEC. The primary purpose of the filing is to report an application for the quotation of securities (ATH) as detailed in Exhibit 99.1. This administrative filing serves to incorporate the new securities information by reference into the company\'s existing Registration Statements on Form S-8 and Form F-3. The document is signed by Julian Babarczy, the Chairman of the Board. While the filing confirms an application for the quotation of securities, it does not provide specific details regarding the volume of shares, the pricing, or the specific purpose of the issuance within the provided text. The filing is standard for a foreign private issuer maintaining its regulatory compliance and registration status in the United States while pursuing capital market activities. No clinical trial updates or regulatory milestones were disclosed in this specific report.